GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solco Biomedical Co Ltd (XKRX:043100) » Definitions » Piotroski F-Score

Solco Biomedical Co (XKRX:043100) Piotroski F-Score : 3 (As of May. 22, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Solco Biomedical Co Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Solco Biomedical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Solco Biomedical Co's Piotroski F-Score or its related term are showing as below:

XKRX:043100' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Solco Biomedical Co was 7. The lowest was 1. And the median was 3.


Solco Biomedical Co Piotroski F-Score Historical Data

The historical data trend for Solco Biomedical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solco Biomedical Co Piotroski F-Score Chart

Solco Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 2.00 2.00 3.00

Solco Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 4.00 3.00 3.00

Competitive Comparison of Solco Biomedical Co's Piotroski F-Score

For the Medical Devices subindustry, Solco Biomedical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solco Biomedical Co's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Solco Biomedical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Solco Biomedical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -1466.252 + -1485.708 + -15317.847 + -56.515 = ₩-18,326 Mil.
Cash Flow from Operations was -2279.878 + -2307.308 + -1314.681 + 0 = ₩-5,902 Mil.
Revenue was 7070.816 + 6265.898 + 7482.363 + 6902.268 = ₩27,721 Mil.
Gross Profit was 2910.153 + 2584.199 + -3014.365 + 2743.131 = ₩5,223 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(54660.132 + 52615.987 + 53842.054 + 50676.951 + 58289.892) / 5 = ₩54017.0032 Mil.
Total Assets at the begining of this year (Mar23) was ₩54,660 Mil.
Long-Term Debt & Capital Lease Obligation was ₩0 Mil.
Total Current Assets was ₩31,901 Mil.
Total Current Liabilities was ₩26,959 Mil.
Net Income was -936.67 + -800.852 + -7085.007 + -1696.436 = ₩-10,519 Mil.

Revenue was 6070.536 + 5630.501 + 6108.65 + 6059.102 = ₩23,869 Mil.
Gross Profit was 2221.867 + 1119.817 + 2124.886 + 2506.009 = ₩7,973 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(58300.157 + 58071.278 + 57948.223 + 56435.287 + 54660.132) / 5 = ₩57083.0154 Mil.
Total Assets at the begining of last year (Mar22) was ₩58,300 Mil.
Long-Term Debt & Capital Lease Obligation was ₩9,875 Mil.
Total Current Assets was ₩30,549 Mil.
Total Current Liabilities was ₩16,097 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Solco Biomedical Co's current Net Income (TTM) was -18,326. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Solco Biomedical Co's current Cash Flow from Operations (TTM) was -5,902. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-18326.322/54660.132
=-0.33527768

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-10518.965/58300.157
=-0.18042773

Solco Biomedical Co's return on assets of this year was -0.33527768. Solco Biomedical Co's return on assets of last year was -0.18042773. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Solco Biomedical Co's current Net Income (TTM) was -18,326. Solco Biomedical Co's current Cash Flow from Operations (TTM) was -5,902. ==> -5,902 > -18,326 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=0/54017.0032
=0

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=9874.96/57083.0154
=0.17299296

Solco Biomedical Co's gearing of this year was 0. Solco Biomedical Co's gearing of last year was 0.17299296. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=31900.646/26959.449
=1.18328257

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=30549.078/16096.684
=1.89784915

Solco Biomedical Co's current ratio of this year was 1.18328257. Solco Biomedical Co's current ratio of last year was 1.89784915. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Solco Biomedical Co's number of shares in issue this year was 0. Solco Biomedical Co's number of shares in issue last year was 66.107. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5223.118/27721.345
=0.18841503

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=7972.579/23868.789
=0.3340169

Solco Biomedical Co's gross margin of this year was 0.18841503. Solco Biomedical Co's gross margin of last year was 0.3340169. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=27721.345/54660.132
=0.5071584

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=23868.789/58300.157
=0.40941209

Solco Biomedical Co's asset turnover of this year was 0.5071584. Solco Biomedical Co's asset turnover of last year was 0.40941209. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Solco Biomedical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Solco Biomedical Co  (XKRX:043100) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Solco Biomedical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Solco Biomedical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Solco Biomedical Co (XKRX:043100) Business Description

Traded in Other Exchanges
N/A
Address
34-6 Keumam-ri, Seotan-myeon, Gyeonggi-do, Pyeongtaek, KOR, 451-852
Solco Biomedical Co Ltd operates in the medical devices industry in South Korea. The products offered by the company include dressing and tissue forceps, scissors, needle holders, intestinal forceps, self-retaining retractors, hooks, and knife handles.

Solco Biomedical Co (XKRX:043100) Headlines

No Headlines